Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19 (ECMO-COVID-19)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them [ Time Frame: Files analysed retrospectily from March 1st, 2020 to April 15, 2020 will be examined ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Adult patients with a COVID-19 diagnosis by RT-PCR
Patient over the age of 18;
Diagnostic COVID-19 by RT-PCR;
Hospitalisation in resuscitation for the management of complications related to COVID-19